NBY Novabay Pharmaceuticals Inc.
- 0 P/E
- 13.17 P/S
- 9.93 P/B
- -0.401 EPS
- -2,638.06% Cash ROIC
- 4.98 Cash Ratio
- 0 / 0% Dividend
- 445,247.00 Avg. Vol.
- 25.77M Shares
- 53.7M Market Cap.
NovaBay Pharmaceuticals Inc., a clinical stage biotechnology company, engages in developing proprietary and patented topical Aganocide compounds for the treatment and prevention of various infections without causing bacterial resistance. Its Aganocide compounds are synthetic anti-infective product candidates with equivalent activity to the active antimicrobial molecules generated within white bloo...
Seeking Alpha - 11 hours ago
4-traders (press release) - Nov 19, 2013
GlobeNewswire (press release) - Dec 2, 2013
GlobeNewswire (press release) - Nov 14, 2013
4-traders (press release) - 8 hours ago
Techsonian (press release) - Nov 19, 2013
Markets Emerging - Nov 20, 2013
Ticker Report - Dec 5, 2013
Marketwired (press release) - Nov 15, 2013
Newsday - Dec 4, 2013